Otonomy Reports Second Quarter 2016 Financial Results and Provides Corporate Update
August 04, 2016 16:09 ET
|
Otonomy, Inc.
SAN DIEGO, Aug. 04, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
Otonomy to Present Results for AuriPro(TM) Phase 3 and OTO-104 Phase 2b Clinical Trials at 2015 AAO-HNSF Annual Meeting
September 24, 2015 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, Sept. 24, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy Announces Successful End-of-Phase 2 Meeting With the FDA for OTO-104 in Meniere's Disease
September 09, 2015 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, Sept. 9, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy Appoints Dean Hakanson, M.D., as Chief Medical Officer
April 01, 2015 07:00 ET
|
Otonomy, Inc.
SAN DIEGO, April 1, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy Reports Fourth Quarter and Full Year 2014 Financial Results and Provides Corporate Update
March 18, 2015 16:14 ET
|
Otonomy, Inc.
SAN DIEGO, March 18, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy to Report Fourth Quarter and Full Year 2014 Financial Results and Provide Corporate Update
March 12, 2015 08:00 ET
|
Otonomy, Inc.
SAN DIEGO, March 12, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy Announces Closing of Follow-on Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
January 28, 2015 16:02 ET
|
Otonomy, Inc.
SAN DIEGO, Jan. 28, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy Announces Pricing of Follow-on Public Offering
January 22, 2015 20:34 ET
|
Otonomy, Inc.
SAN DIEGO, Jan. 22, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy Announces Launch of Follow-on Public Offering
January 21, 2015 16:01 ET
|
Otonomy, Inc.
SAN DIEGO, Jan. 21, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy Provides Corporate and Product Pipeline Update
January 08, 2015 16:55 ET
|
Otonomy, Inc.
SAN DIEGO, Jan. 8, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...